Standard BioTools Inc. Receives Nasdaq Notice Over Minimum Bid Price Deficiency

What Happened
Standard BioTools Inc. (NASDAQ: LAB) filed an 8-K on July 24, 2026 reporting that Nasdaq’s Listing Qualifications Department notified the company it is not in compliance with the $1.00 minimum bid price requirement after a 30-business-day stretch of closing bids below $1.00. The notice begins an automatic 180-calendar-day compliance period; the company has until January 19, 2027 to regain compliance for at least 10 consecutive business days. Trading of LAB shares continues uninterrupted on Nasdaq.

Key Details

• Nasdaq rule involved: minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1); automatic 180-day compliance period per Rule 5810(c)(3)(A).
• Compliance deadline: 180 days from the Notice, specified in the filing as until January 19, 2027.
• Cure conditions: regain a closing bid ≥ $1.00 for at least 10 consecutive business days; if other listing standards are met, the company may seek an additional 180-day period but would need to transfer to The Nasdaq Capital Market, pay an application fee, and provide written notice (a reverse stock split is an example remedy).
• Immediate effect: the Notice does not delist the stock now, does not interrupt trading under ticker “LAB,” and does not change SEC reporting obligations.

Why It Matters
This is a material compliance matter investors should watch because failure to regain the required share price could lead to delisting proceedings or corporate actions (for example, a reverse stock split) to restore compliance. For now, trading and business operations continue normally, but the company’s share liquidity, investor perception, and potential inclusion in certain funds could be affected if the deficiency is not cured. The company stated it intends to attempt to regain compliance but gave no assurance it will succeed.